Akero Therapeutics, Inc. (AKRO) P/E Ratio History
Insufficient DataValuation data unavailable. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AKRO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AKRO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AKRO P/E vs Peers
MASH & Liver Drugs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $12B | 26.2 | 1.14Best | -25% | |
| $21B | 7.9Lowest | - | +207%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AKRO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AKRO — Frequently Asked Questions
Quick answers to the most common questions about buying AKRO stock.
What is AKRO's P/E ratio?
Akero Therapeutics, Inc. (AKRO) trailing twelve-month P/E ratio is N/A, based on TTM diluted EPS of N/A. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is AKRO stock overvalued or undervalued?
AKRO current P/E: N/A. 5-year average P/E: N/A. Percentile: N/A.
Is AKRO stock expensive?
AKRO is fairly valued relative to its own history. The current P/E of N/A is near the 5-year average of N/A (N/A percentile of historical range).
What is AKRO's historical P/E range?
Over the past 5 years, AKRO's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of N/A places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does AKRO's P/E compare to the S&P 500?
AKRO current P/E: N/A. S&P 500 median P/E: 21.8x.
How does AKRO's valuation compare to Healthcare peers?
Akero Therapeutics, Inc. P/E of N/A can be benchmarked against Healthcare peers in the comparison table on this page.
What is AKRO's PEG ratio?
AKRO PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AKRO's earnings yield?
AKRO earnings yield is N/A, the inverse of its N/A P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.